# **RSC Advances**



View Article Online

View Journal | View Issue

# PAPER

Check for updates

Cite this: RSC Adv., 2017, 7, 18844

Received 22nd January 2017 Accepted 23rd March 2017

DOI: 10.1039/c7ra00925a

rsc.li/rsc-advances

## Introduction

Because of their unique physiochemical properties, nanomaterials have been widely used in biomedical applications, especially in various imaging techniques including ultrasound imaging (USI),<sup>1</sup> magnetic resonance imaging (MRI),<sup>2,3</sup> computed tomography (CT),<sup>4,5</sup> positron emission tomography (PET),<sup>6</sup> fluorescence imaging (FLI)<sup>7</sup> and photoacoustic tomography (PAT).8 Among the above imaging techniques, CT has been used as one of the most commonest imaging modality with high resolution and detailed 3D visual structure of tissues of interest.9 However, every imaging technology possesses its own inherent advantages and limitations. The main weakness for CT imaging is low sensitivity for low density soft tissues.<sup>10</sup> Integrating two or more imaging modalities on one nanostructure could provide more comprehensive information for better diagnosis and therapy. MRI is another useful imaging tool for whole-body diffusion-weighted imaging in disease diagnosis, especially in soft tissues with excellent spatial

# Facile synthesis of multifunctional Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub>@Au magneto-plasmonic nanoparticles for MR/CT dual imaging and photothermal therapy

Xuemei Hou,†<sup>ab</sup> Xuandong Wang, <sup>(1)</sup>†<sup>\*ab</sup> Rong Liu,<sup>ab</sup> Huicong Zhang,<sup>ab</sup> Xiaolong Liu<sup>\*c</sup> and Yun Zhang<sup>\*ab</sup>

Magneto-plasmonic nanoparticles have exhibited great potential in cancer diagnosis and therapy because of their excellent magnetic and optically activable plasmonic properties. However, it is still a great challenge to combine these two components in one single-nanoparticle. In this work, we developed a facile method to synthesize monodispersed and uniform theranostic agents of  $Fe_3O_4$ (a)SiO<sub>2</sub>(a)GNSs-PEG (PMGNSs) nanoparticles. The as-synthesized PMGNSs composed of a superparamagnetic  $Fe_3O_4$  inner core, silica as the midlayer and coated with gold nanoshells at the outside, with uniform size distribution of less than 100 nm. It has been demonstrated to be with excellent magnetic resonance (MR) and computed tomography (CT) imaging contrast abilities at different concentrations. Meanwhile, the as-synthesized PMGNSs exhibited high stability with no significant change of photothermal performance after five laser ON/OFF cycles, and high photothermal conversion ability with temperature increase of 40 °C under 808 nm laser irradiation at 2 W cm<sup>-2</sup> for 10 min at the concentration of 160  $\mu$ g ml<sup>-1</sup>. Furthermore, *in vitro* photothermal therapy ability has also been demonstrated on HePG2 cancer cells.

resolution, offering high sensitivity information.<sup>11</sup> Combining MR and CT imaging could compensate the limitations for each other, and the dual contrast agent could be simultaneously used in the precision diagnosis of various diseases.

In recent years, Fe<sub>3</sub>O<sub>4</sub>/Au nanocomposites have been demonstrated to be important MRI/CT theranostic agents due to their inherent advantages.<sup>12,13</sup> In such nanocomposites, the magnetic component is often used as a T2-weighted MRI contrast for cancer diagnosis and therapy because of its contrast enhancement and high relaxivity properties. Magnetic nanoparticles (MNPs) also could be easily manipulated by an external magnetic field for targeted drug delivery and for magnetic hyperthermia therapy.14,15 However, there are still some weaknesses of MNPs which could be rapidly cleared by macrophages preventing their trans-endothelia passage and tissue penetration.16 As the component of the Fe<sub>3</sub>O<sub>4</sub>/Au nanocomposites, gold nanoparticles (GNPs) have high atomic number for high X-ray absorption, making them to be helpful in enhancing computed tomography (CT) imaging.17 GNPs have been widely used in biomedical applications because of their biocompatibility, high stability and could be easily functionalized with the biomarkers for targeting tumor cells.18,19 In addition, GNPs with the localized surface plasmon resonance (LSPR)<sup>20</sup> have been demonstrated great potential applications in near-infrared (NIR) laser-induced photothermal therapy (PTT), which is a minimally therapy, depending on absorbing the NIR light and converting the optical energy into heat to kill the cancer cells by thermal ablation.<sup>21</sup> For example, gold nanocages,<sup>22,23</sup> gold

<sup>&</sup>quot;Key Laboratory of Design and Assembly of Functional Nanostructures, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002,

P. R. China. E-mail: wangxd@fjirsm.ac.cn; zhangy@fjirsm.ac.cn

<sup>&</sup>lt;sup>b</sup>Department of Translational Medicine, Xiamen Institute of Rare Earth Materials, Chinese Academy of Sciences, Xiamen 361024, P. R. China

<sup>&</sup>lt;sup>c</sup>The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China. E-mail: xiaoloong.liu@gmail.com

<sup>†</sup> Xuemei Hou and Xuandong Wang contributed equally.

#### Paper

nanorods,<sup>24,25</sup> gold nanostars<sup>26,27</sup> and gold nanoshells<sup>28,29</sup> have been reported with strong absorption in NIR region and high thermal efficiency, making them ideal PTT agents. In the above gold nanostructures, gold nanoshells have the obvious advantages: biocompatible, monodisperse, tunable visible-NIR plasmonic spectrum and high stability.<sup>30,31</sup> Therefore, it is an urgent need to combine MNPs and gold nanoshells on one nanostructure, which could be used for both MR/CT imaging guided photothermal therapy.

Until now, several strategies have been reported for the synthesis of magnetic nanoparticles coated with gold nanoshells (MGNSs), such as direct coating, seed growth method. Direct coating MNPs with gold nanoshells seems to be a simple method, however, it is often a difficult task to combine two incompatible surfaces and results in poor dispersion, and it fails to generate MGNSs with NIR responses, as the thin gold layer without dielectric layer results in GNPs-like plasmonic response in visible region.<sup>32,33</sup> Thus, the midlayer of aminomodified silica or polymer was often used to form gold nanoshells by seed growth.<sup>34-36</sup> However, some problems still present in the preparation of MGNSs, such as most of size is larger than 100 nm, the morphology is irregular, which may influence further biomedical applications.37,38 Successful preparation of suitable size and uniform MGNSs by a facile method still remains to be a challenge.

In this research, we report a facile method to synthesize monodisperse, uniform and well-defined nanostructure of PMGNSs nanoparticles with appropriate size (less than 100 nm) by seed growth method. The PMGNSs nanoparticles were composed of a superparamagnetic Fe<sub>3</sub>O<sub>4</sub> inner core, silica as the midlayer and coated with gold nanoshells by seed mediated growth method. They have been demonstrated to be effective MR and CT imaging contrast agents. High stability was also displayed with no significant change after five laser ON/OFF cycles, and high photothermal effect with temperature increase of 40  $^{\circ}$ C under 808 nm laser irradiation at 2 W cm<sup>-2</sup> for 10 min at the concentration of 160  $\mu$ g ml<sup>-1</sup>. Low cytotoxicity was demonstrated that the viability more than 90% at the concentration of 200 µg ml<sup>-1</sup> of PMGNSs. The viability could reduce to 40% under 808 nm laser irradiation at 2 W cm<sup>-2</sup> for 3 min at the concentration of 200 µg ml<sup>-1</sup>. Comprehensive evaluation has shown that the PMGNSs nanoparticles are with good biocompatibility and great potential to be used as MR/CT dual-modal imaging guided photothermal therapy agents for biomedical applications.

## Experimental

#### Materials

Ferric chloride hexahydrate (FeCl<sub>3</sub>· $6H_2O$ , 99%), oleic acid (OA, AR), 1-octadecene (ODE, 90.0%), cyclohexane (C<sub>6</sub>H<sub>12</sub>, 99.5%), sodium oleate (NaOA, CP), hexane (C<sub>6</sub>H<sub>12</sub>, 97.0%), ammonia solution (NH<sub>3</sub>·H<sub>2</sub>O, 25–28%), acetone (C<sub>3</sub>H<sub>6</sub>O, 99.5%), sodium hydroxide (NaOH, 96.0%), potassium carbonate (K<sub>2</sub>CO<sub>3</sub>, 99.0%), hydroxylammonium chloride (NH<sub>2</sub>OH·HCl, 98.5%) were purchased from Aladdin Industrial Inc. Tetraethyl orthosilicate (TEOS, 99.0%), polyoxyethylene (5) nonylphenylether

(NP-5), tetrakis(hydroxymethyl)phosphonium chloride (THPC, 80% solution in H<sub>2</sub>O), hydrogen tetrachloroaurate(m) hydrate (HAuCl<sub>4</sub>·3H<sub>2</sub>O, 99.9% metals basis) were purchased from Sigma-Aldrich. mPEG-SH ( $M_w = 2000$ ) was purchased from Biomatrik Inc. HepG2 cells (hepatocellular carcinoma) were purchased from ATCC (Manassas, VA). The cells were cultured in RPMI 1640 medium with high glucose (ATCC, Manassas, VA) supplemented with 10% FBS (PAN-Biotech GmbH) and 100 IU ml<sup>-1</sup> penicillin–streptomycin (Manassas, VA). Phosphate buffered saline (1X) was purchased from HyClone. Cell Counting Kit-8 (CCK-8) and Calcein-AM/PI Double Stain Kit were purchased from Dojindo Laboratories (Japan). The ultrapure water with a resistivity of 18.2 M $\Omega$  cm was obtained from Milli-Q Gradient System (Millipore, Bedford, MA, USA) and used for all of the experiments.

#### Characterization

Transmission electron microscopy (TEM) images were taken on a JEM-2100 system at an accelerating voltage of 200 kV. Fourier transform infrared spectra (FT-IR) were performed by a Thermo Nicolet iS50 FT-IR Spectrometer over a potassium bromide pellet, and the diffuse reflectance spectra were scanned over the range from 400 cm<sup>-1</sup> to 4000 cm<sup>-1</sup>. The UV-Vis-NIR spectra were recorded by a Agilent Cary 5000 UV-Vis-NIR Spectrophotometer. The Fe and Au element component analysis were obtained on the Ultima 2 (Horiba-Jobin Yvon) Inductively Coupled Plasma-Optical Emission Spectrometry. The magnetic properties were performed by hysteresis loops measured under a hysteresis curves tester (VSM: USA model lakeshore 7400). The photothermal performance was verified, when the PMGNSs solution was exposed to 808 nm laser (BTW: diode laser system) and the temperature was recorded by a thermocouple microprobe (STPC-510P, Xiamen Baidewo Technology Co., China). The cellular apoptosis were observed with a confocal laser scanning fluorescence microscopy (Carl Zeiss LSM 780, USA). The MRI was taken on a 9.4 T (Bruker Magnetom) system with different concentrations of PMGNSs solution. The CT imaging was taken on a Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT Mediso nanoScan SC) system by various concentrations of PMGNSs solution.

#### Synthesis of hydrophobic Fe<sub>3</sub>O<sub>4</sub> nanoparticles

The Fe<sub>3</sub>O<sub>4</sub> MNPs were prepared according to a modified thermal-decomposition method.<sup>39</sup> In the synthetic procedure, the iron-oleate complex precursor was firstly prepared, a mixed solution of ultrapure water/ethanol (30 ml/40 ml), FeCl<sub>3</sub>·6H<sub>2</sub>O (5.4 g), NaOA (18.2 g) and hexane (70 ml) were added into conical flask in sequence, keep stirring at 40 °C for 2 h. The resulting solution was separated by a separatory funnel, washed with ultrapure water twice and collected the above organic layer containing the Fe(oleate)<sub>3</sub> precursor complex. Secondly, the Fe(oleate)<sub>3</sub> precursor (6 ml) was added into a three-neckedround-bottomed flask and stirred for 2 h to volatilize solvent under argon flow at room temperature. When the solution turned to viscous, oleic acid (1 ml) and 1-octadecene (30 ml) were added, heating up to 120 °C for 10 min at argon condition to remove the water. Afterwards, the reaction system was heated to 300 °C at the heating rate of 3.3 °C min<sup>-1</sup>, kept stirring for 2 h. The black production of hydrophobic Fe<sub>3</sub>O<sub>4</sub> nanoparticles were washed with ethanol and separated by centrifugation for several times, then collected and redispersed into 10 ml hexane.

# Synthesis of $Fe_3O_4$ (a)SiO<sub>2</sub> core–shell nanoparticles modified with APTES

The Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub> was synthesized by a typical reverse microemulsion method. Briefly, 0.5 ml of NP-5 was dispersed in 8.85 ml cyclohexane and stirred for 30 min at 650 rpm. Subsequently, as-prepared Fe<sub>3</sub>O<sub>4</sub> nanoparticles solution (200 µl) was added into the above mixed one and stirred for 1 h. Then, ammonia solution (1 ml) was dropwise added and stirred for another 1 h. Then, TEOS (0.2 ml) was dropwise added by twice (adding 100 µl per 12 h). Finally, APTES (25 µl) was dropped into the reaction system and the mixture was vigorously stirred at room temperature for another 12 h. The resulting product of Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub> core–shell nanoparticles were collected after centrifuging and washing by ethanol at 9000 rpm 30 min for three times to remove emulsifier, and redispersed in ethanol (5 ml).

# Synthesis of Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub>@GNSs-PEG core/shell/shell nanoparticles (PMGNSs)

In a typical procedure, the MGNSs were formed by the seed growth method. Firstly, gold seeds were prepared by the reduction of HAuCl<sub>4</sub>·3H<sub>2</sub>O with THPC. 0.5 ml of 1 M NaOH was added to 38 ml of ultrapure water and stirred for 3 min. Then, 1 ml of 1% THPC was injected and stirred for 7 min and subsequently 2 ml of 1% HAuCl<sub>4</sub> aqueous solution was added stirring for 2 min. The resulting brown gold seeds were stored at 4 °C. Secondly, gold seeds absorbed on the surface of Fe<sub>3</sub>O<sub>4</sub>@-SiO<sub>2</sub> core-shell nanoparticles. Gold seeds solution (1 ml) was mixed with Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub> (30 µl) for stirring 30 min. Then, the resulted Fe3O4@SiO2@GNPs nanoparticles were collected after centrifuging and washing with water to remove the extra gold seeds, and redispersed in water (1 ml). Thirdly, the gold nanoshells formed by a seed growth method. PVP aqueous solution (120  $\mu$ l, 0.5%) was added into growth media of K<sub>2</sub>CO<sub>3</sub>/HAuCl<sub>4</sub> (5 ml) solution which has been mixed for 12 h, while vigorously stirring for 5 min. Following, the as-prepared MGNPs were added into the above solution and stirred for another 5 min. In the end, as the adding of NH<sub>2</sub>OH · HCl (120 µl, 0.02 M) dropwise into the reaction system the solution changed to bluish green, and stirring for 30 min, indicating that gold nanoshells were formed, the MGNSs were washed with water. mPEG-SH was used to modify the surface of MGNSs to decrease the biotoxicity of nanomaterials. 2 mM K<sub>2</sub>CO<sub>3</sub> (500 µl) and 1 mM mPEG-SH (100  $\mu$ l) were mixed together and stirred for some hours. Then, the MGNSs (5 ml) were added and stirred overnight at room temperature. Finally, the resulted MGNPs modified with mPEG-SH (PMGNSs) were collected after the centrifuging and washing with water and ethanol three times.

#### Cell culture and cytotoxicity assay

Human liver carcinoma cells of HepG2 were maintained in Roswell Park Memorial Institute (RPMI-1640), supplemented with 10% fetal bovine serum (FBS) at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub>. The cell culture media was supplemented with 100 unit per ml penicillin and 100  $\mu$ g ml<sup>-1</sup> streptomycin to inhibit the growth of other extraneous bacteria. For cytotoxicity assay, 5000 cells were seeded in 96-well plates and cultured for 24 h, followed by addition of PMGNSs with different concentrations. After additional 24 h, cell viability was determined by a cell counting kit 8 (CCK-8) assay following the instruction from the manufacturer. All the experiments were carried out for four replicates.

#### Photothermal ablation

Human liver carcinoma cells of HepG2 were seeded in 96-well plates and cultured for 24 h. Subsequently, different concentrations of PMGNSs nanoparticles were injected and cultured for another 24 h. Then, the cells were irradiated with a 808 nm laser at predetermined output power density and duration for 3 min, cultured for one more 24 h and examined the cell viability by CCK-8 assay.

#### In vitro living/dead cell staining

HepG2 cells were firstly seeded into a 96-well plate at 37 °C in a 5% CO<sub>2</sub> atmosphere for 24 h. Then, the cells were washed three times with PBS buffer to remove the dead cells, followed by incubation with PMGNSs at the concentration of 200  $\mu$ g ml<sup>-1</sup> dispersed in culture medium at 37 °C for 4 h. Subsequently, the HepG2 cells were washed by PBS buffer to remove non-uptaken PMGNSs for three times, and then exposed to 808 nm laser (2 W cm<sup>-2</sup>) for 3 min. After the laser irradiation, the cells were incubated with fresh culture medium at 37 °C for 2 h. Then, the cells were stained with the calcine AM/propidium iodide (PI) to evaluate cell apoptosis induced by the photothermal treatment of the PMGNSs and observed by a confocal lasers scanning fluorescence microscope (Carl Zeiss LSM 780, USA).

#### In vitro MR imaging of PMGNSs

To investigate the MR imaging function of the PMGNSs, an *in vitro*  $T_2$ -weighted MR imaging experiment was conducted on a 9.4 T (Bruker Magnetom) system. Tubes containing a series concentration of PMGNSs solution were measured, and water was used as the control. The signal strength is indicated by the brightness of the images.

#### In vitro CT imaging of PMGNSs

To examine the CT imaging function of the PMGNSs, an *in vitro* CT imaging experiment was conducted on a single photon emission computed tomography/computed tomography (Mediso nanoScan SC) system. Tubes containing the PMGNSs solution were arrayed by increasing concentration, and water was placed as the control. The signal strength is indicated by the different colors of the images.

### **Results and discussion**

#### Synthesis and characterization of PMGNSs

The synthesis process of PMGNSs included four steps, schematic diagram was shown in Fig. 1a. Briefly, monodispersed hydrophobic Fe<sub>3</sub>O<sub>4</sub> nanoparticles were prepared by a modified thermal decomposition method with the average diameter of 12 nm in the first step (Fig. 1b). Secondly, MNPs were successfully encapsulated in silica by reverse microemulsion method, the main mechanism is that NP-5 as a surfactant, ligand exchange with the oleic acid group of Fe<sub>3</sub>O<sub>4</sub>, and then hydrolyzed TEOS during coating silica.40 In the meantime, APTES was used to modify the surface of Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub> nanoparticles, for further step absorbing of the gold seeds and the growth of gold nanoshells. The Fe<sub>3</sub>O<sub>4</sub>(a)SiO<sub>2</sub> nanoparticles display a well defined core-shell nanostructure coated one single Fe<sub>3</sub>O<sub>4</sub> perfectly in the center and surrounded by a homogeneous silica layer, corresponding to the thickness of silica shell about 24 nm (Fig. 1c). Silica was mainly used as the modifier and dielectric midlayer. As the homogeneous Fe<sub>3</sub>O<sub>4</sub> nanoparticles synthesized by thermal decomposition method, they were hydrophobic and hard for directly biological applications. The silica coating is a very good surface modifier, because of its excellent biocompatibility, stability, nontoxicity and could easily modified by organosilane coupling agents. Then, small size of gold seeds with 2 nm diameter were attached onto silica modified with APTES through the amine group and electrostatic interaction (Fig. 1d). Finally, the gold nanoshells were formed by seeds mediated growth method,41,42 and the thickness of gold nanoshell is about 15 nm, mPEG-SH modified the MGNSs through Au-SH bonding effects. The whole size of PMGNSs is about 90 nm, which is suitable for biomedical application.



Fig. 1 (a) Schematic diagram of PMGNSs synthesis and PEGylation. TEM images of (b)  $Fe_3O_4$ , (c)  $Fe_3O_4@SiO_2$  nanoparticles, (d)  $Fe_3O_4@-SiO_2@GNPs$ , and (e)  $Fe_3O_4@SiO_2@GNSs-PEG$ .

The UV-VIS-NIR absorption spectra of Fe<sub>3</sub>O<sub>4</sub> (2A-a), Fe<sub>3</sub>-O<sub>4</sub>(a)SiO<sub>2</sub> (2A-b) and Fe<sub>3</sub>O<sub>4</sub>(a)SiO<sub>2</sub>(a)GNSs-PEG (PMGNSs) (2A-c) were shown in Fig. 2A. There are no obvious absorption peaks in Fe<sub>3</sub>O<sub>4</sub> (2A-a) and Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub> (2A-b). While, there is a broad surface plasmon resonance characteristic peak of gold nanoshells at the range from 500 nm to the near infrared region (2Ac), indicating that gold nanoshells have been successfully assembled. To confirm the step-by-step synthesis of PMGNSs, the FT-IR spectra of Fe<sub>3</sub>O<sub>4</sub>, Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub> and PMGNSs were measured. As shown in Fig. 2B, the FT-IR spectra of OA capped  $Fe_3O_4$  (Fig. 2B-a) showed the characteristic peaks of 592 cm<sup>-1</sup> was contributed to the Fe–O vibration, 2851 and 2922 cm<sup>-1</sup> were respectively contributed to the CH<sub>3</sub> and the CH<sub>2</sub> stretching vibrations. The two peaks of 1634 and 1409 cm<sup>-1</sup> were related to antisymmetric vibration and symmetric vibration of COOgroup. With the coating of silica (Fig. 2B-b), the bands at 1096 and 953 cm<sup>-1</sup> attributed to antisymmetric vibration of Si–O–Si, 795 and 464 cm<sup>-1</sup> symmetric vibration of Si–O, stretch vibration of Fe-O bonds, there is a shift with the exchange of surface ligands, which also indicate the silica coating on the surface of Fe<sub>3</sub>O<sub>4</sub> NPs through ligand exchange. As is shown in Fig. 2B-c characteristic peaks of 3413, 2858, 2919 and 1078 cm<sup>-1</sup> were respectively contributed to the O-H stretching, CH<sub>3</sub> stretching, CH<sub>2</sub> stretching and C-O stretching vibrations, which are the typical infrared absorption band of mPEG-SH. As the use of hydroxylamine hydrochloride for the growth of gold nanoshells, the absorption band of 1633  $\text{cm}^{-1}$  (bending vibration of  $-\text{NH}_2$ ) was also observed from the FT-IR spectra. According to the result, it further revealed we successfully obtained the PMGNSs.

As the PMGNSs have a broad surface plasmon resonance (SPR) peak at the range from 500 nm to the NIR region, which makes them to be potential used for PTT. To study the photo-thermal property of PMGNSs, the temperature increasing profiles of PMGNSs solution generated by NIR laser irradiation were carried out. The temperature profiles of ultrapure water and PMGNSs solution with different concentrations (Fig. 3a) and different power density 1 W cm<sup>-2</sup>, 2 W cm<sup>-2</sup> and 4 W cm<sup>-2</sup> (Fig. 3b) as a function of 808 nm laser irradiation time for 10 min, the temperature rises when increasing the power density of the laser irradiation. We also investigated the temperature profiles of PMGNSs aqueous solutions with different concentrations (20, 40, 80, 160 and 320  $\mu$ g ml<sup>-1</sup>) and ultrapure water by a NIR laser irradiation (808 nm at 2 W cm<sup>-2</sup> for 10 min). As increasing the concentrations of PMGNSs in the



Fig. 2 The UV-VIS-NIR absorption spectra of  $Fe_3O_4$  (A-a),  $Fe_3O_4$ (a-SiO<sub>2</sub> (A-b), PMGNSs (A-c), and the FT-IR spectra of  $Fe_3O_4$  (B-a),  $Fe_3-O_4$ (BSiO<sub>2</sub> (B-b) and PMGNSs (B-c).



Fig. 3 Photothermal and magnetic profiles of PMGNSs. (a) Temperature profiles of ultrapure water and PMGNSs solution with different concentrations (20, 40, 80, 160 and 320  $\mu$ g ml<sup>-1</sup>) as a function of 808 nm laser irradiation time for 10 min at a power density of 2 W cm<sup>-2</sup>; (b) temperature profiles of PMGNSs solution with different power density (1, 2 and 4 W cm<sup>-2</sup>) as a function of 808 nm laser irradiation time for 10 min with the concentration of 80  $\mu$ g ml<sup>-1</sup>; (c) temperature monitoring of a PMGNSs aqueous suspension at the concentration of 80  $\mu$ g ml<sup>-1</sup> during for successive cycles of an ON/ OFF laser at a power density of 2 W cm<sup>-2</sup>; (d) magnetic hysteresis curves of PMGNSs and attract by a magnet.

aqueous solution, the temperature rising remarkably. The photothermal heating curves showed a strong laser-powerdependent photothermal effect for PMGNSs with the highest temperature increment up from to 79.1 °C at the concentration of 320 µg ml<sup>-1</sup>. In obvious contrast, only 1.0 °C of the temperature increasing was observed for ultrapure water at the same treatment conditions. These results indicate that PMGNSs can rapidly and efficiently convert the energy from 808 nm laser into thermal energy. The temperature profiles of five cycles of heating under 2 W cm<sup>-2</sup> laser irradiation and cooling down (Fig. 3c). After five cycles, the temperature of PMGNSs aqueous solution with the concentration of 80  $\mu$ g ml<sup>-1</sup> can still could rise up to 46.4 °C, as a function of 808 nm laser irradiation time for 10 min at the power density of 2 W cm<sup>-2</sup>. The heating profiles confirmed that the PMGNSs have excellent photothermal stability. The magnetic property of PMGNSs was evaluated by a vibrating sample magnetometer (VSM) at room temperature (Fig. 3d). The magnetization curves showed that the PMGNSs have no evident remanence or coercivity, suggesting their superparamagnetic behaviors, it also means that the PMGNSs have the potential been used as magnetic resonance imaging contrasts. The saturation magnetization  $(M_s)$  value of PMGNSs was  $0.52 \text{ emu g}^{-1}$ . From the inset image of Fig. 3d, the PMGNSs can be easily attracted aside by a magnet.

Cytotoxicity evaluation and photothermal therapy of PMGNSs. Nontoxicity or low toxicity was the prerequisite of an ideal photothermal agent for the biological application. To evaluate the cytotoxicity of PMGNSs, the Cell Counting Kit-8 (CCK-8) assay method was used. HepG2 liver cancer cells were incubated with PMGNSs of gradient concentrations. According to the cells viabilities in Fig. 4, no obvious differences were found with and without the presence of PMGNSs, indicating that the PMGNSs be with good biocompatibility. The cell viability with the different concentrations (0, 12.5, 25, 50, 100 and 200  $\mu$ g ml<sup>-1</sup>) of PMGNSs exceeded 90% after incubation for 24 h. The results demonstrate that the PMGNSs have low cytotoxicity. In the presence of laser irradiation, PMGNSs generate obvious photothermal conversion effect under the magnetic field. At a concentration of 200  $\mu$ g ml<sup>-1</sup>, cell viability was reduced to 40%, which demonstrated the excellent photothermal killing effect of PMGNSs with the NIR laser irradiation (808 nm, 2 W cm<sup>-2</sup>) for 3 min at the presence of magnetic field for targeted therapy.

To further evaluate the localized magnetic targeted phototherapeutic effect of PMGNSs, HepG2 cells were incubated with 200  $\mu$ g ml<sup>-1</sup> PGMNSs for 4 h, then irradiated with 808 nm laser at 2 W cm<sup>-2</sup> for 3 min, the cells were costained by calcine AM and propidium iodide (PI) to differentiate live (green) and dead (red) cells, respectively, and imaged by a confocal fluorescence microscope for living/dead cells at different condition. As shown in Fig. 5, no obvious viability was observed when HepG2 cells were treated with laser, PMGNSs alone or PMGNSs under magnet comparing with the negative control (Fig. 5a-d). When HepG2 cells treated with PMGNSs and laser irradiation, a large number of cells were dead by thermal ablation (Fig. 5e), even more cellular death when plus a magnet for targeted photothermal therapy (Fig. 5f). These experiments demonstrate the significant phototherapeutic effect of the PMGNSs, they could be used as a high effective PTT agent for treatment of cancer cells.

In vitro MR/CT imaging of PMGNSs. To investigate the MRI enhancing function of PMGNSs, an *in vitro*  $T_2$ -weighted MRI experiment was measured by a 9.4 T (Bruker Magnetom) system. Different concentrations of PMGNSs solution were 0, 0.22 mM, 0.44 mM, 0.88 mM and 1.76 mM of Fe (quantitatively measured by ICP-OES), ultrapure water was used as the control. As shown in Fig. 6a, the MRI signal in the PMGNSs was observed with the contrast of ultrapure water, and the  $T_2$ -weighted magnetic resonance images became darker, as the increasing of the concentration of PMGNSs. The results indicated that the PMGNSs shortened the  $T_2$  relaxation time. And through the research of the



Fig. 4 Cell viability of HepG2 treated with different concentrations (0, 12.5, 25, 50, 100 and 200  $\mu$ g ml<sup>-1</sup>) of PMGNSs, PMGNSs + magnet, PMGNSs + laser and PMGNSs + magnet + laser.



Fig. 5 Confocal fluorescence images of HepG2 cells with different treatments stained by calcine AM and propidium iodide (PI): (a) HepG2 cells without treatment and (b) HepG2 cells incubated with 200  $\mu$ g ml<sup>-1</sup> PMGNSs only without treatment; (c) HepG2 cells irradiated with 200  $\mu$ g ml<sup>-1</sup> PMGNSs without laser irradiation under magnet; (d) HepG2 cells treated with laser irradiation; (e) HepG2 cells 200  $\mu$ g ml<sup>-1</sup> PMGNSs irradiated with laser irradiation; (f) HepG2 cells irradiated with 200  $\mu$ g ml<sup>-1</sup> PMGNSs with laser irradiation under magnet. Laser irradiation (808 nm, 2 W cm<sup>-2</sup>) for 3 minutes. The living/dead staining for viability shows dead cells as red while alive cells as green. Scale bar = 50  $\mu$ m.



Fig. 6 (a)  $T_2$ -Weighted MR images of PMGNSs at various concentrations of Fe. Signal strength is indicated by the brightness of the images; (b) single photon emission computed tomography/computed tomography (SPECT/CT) phantom images of PMGNSs at different concentrations of Au. Signal strength is indicated by the various colors of the images.

MRI signal variation as the increasing concentration of the PMGNSs, the longitudinal rates were analyzed, the measured  $r_2$  value was 41.077 mM s<sup>-1</sup> (Fig. 6a) by plotting  $1/T_2$  against the concentration of Fe in the solution. Therefore, these results indicated that PMGNSs have the great potential application for MRI.

Since the high atomic number and electron density, gold component has the property of high X-ray attenuation. To demonstrate the CT enhancing capability of PMGNSs, the SPECT/CT *in vitro* experiment was implement by a Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT Mediso nanoScan SC) system. The inset illustration of Fig. 6b presents the *in vitro* phantom and colormapped CT images using various concentrations of Au from 0 to 22.80 mM (quantitatively measured by ICP-OES). As the increase of PMGNSs, the color obviously changed as the contrast enhancement signals form blue violet-yellow-red. From the quantitative measurement of the X-ray attenuation ability of PMGNSs, the HU values of different concentrations were measured. From these data, we could come to a conclusion that the PMGNSs could act as good CT imaging contrast agents.

# Conclusions

In summary, we have successfully fabricated monodispersed, uniform and elaborate core/shell/shell PMGNSs nanoparticles. The obtained nanoparticles could be well dispersed in the aqueous solution and possess excellent superparamagnetic and plasmonic properties, enabling the PMGNSs nanoparticles be used as the contrast agents for MR/CT dual imaging. At the same time, PMGNSs nanoparticles have high photothermal therapy effect and high stability. Low biotoxicity will pave ways for providing a multifunctional and versatile cancer theranostic platform combining MR/CT imaging targeted effective photothermal therapy.

# Conflict of interest

The authors declare no competing financial interest.

## Acknowledgements

The work was supported by the National Natural Science Foundation of China (No. 31400699 and 61605209), and the Natural Science Foundation of Fujian Province of China (No. 2014J01142 and 2015J05172).

## References

- K. H. Min, H. S. Min, H. J. Lee, D. J. Park, J. Y. Yhee, K. Kim,
   I. C. Kwon, S. Y. Jeong, O. F. Silvestre, X. Chen, Y. S. Hwang,
   E. C. Kim and S. C. Lee, *ACS Nano*, 2015, 9, 134–145.
- 2 H. B. Na, I. C. Song and T. Hyeon, *Adv. Mater.*, 2009, 21, 2133-2148.
- 3 Z. Zhao, Z. Zhou, J. Bao, Z. Wang, J. Hu, X. Chi, K. Ni, R. Wang, X. Chen, Z. Chen and J. Gao, *Nat. Commun.*, 2013, 4, 2266.
- 4 Y. Liu, K. Ai and L. Lu, Acc. Chem. Res., 2012, 45, 1817-1827.
- 5 A. Jakhmola, N. Anton and T. F. Vandamme, *Adv. Healthcare Mater.*, 2012, **1**, 413–431.
- 6 X. Sun, W. Cai and X. Chen, Acc. Chem. Res., 2015, 48, 286-294.
- 7 Z. Li, Q. Sun, Y. Zhu, B. Tan, Z. P. Xu and S. X. Dou, *J. Mater. Chem. B*, 2014, **2**, 2793.
- 8 D. Zhang, M. Wu, Y. Y. Zeng, N. S. Liao, Z. X. Cai, G. Liu, X. L. Liu and J. F. Liu, *J. Mater. Chem. B*, 2016, 4, 589–599.
- 9 I. Willekens, E. Van De Casteele, N. Buls, F. Temmermans,
  B. Jansen, R. Deklerck and J. de Mey, *BMC Cancer*, 2014, 14, 9.
- 10 A. S. P. Lin, A. W. Palmer, C. L. Duvall, G. C. Robertson, M. E. Oest, B. Rai, M. E. Levenston and R. E. Guldberg, Advanced Bioimaging Technologies in Assessment of the Quality of Bone and Scaffold Materials: Techniques and Applications, 2007, pp. 239–256.
- 11 A. Datir, S. L. J. James, K. Ali, J. Lee, M. Ahmad and A. Saifuddin, *Clin. Radiol.*, 2008, **63**, 373–378.

Paper

- 12 H. Cai, K. Li, J. Li, S. Wen, Q. Chen, M. Shen, L. Zheng, G. Zhang and X. Shi, *Small*, 2015, 11, 4584–4593.
- 13 W. Feng, X. Zhou, W. Nie, L. Chen, K. Qiu, Y. Zhang and C. He, *ACS Appl. Mater. Interfaces*, 2015, 7, 4354–4367.
- 14 C. S. S. R. Kumar and F. Mohammad, *Adv. Drug Delivery Rev.*, 2011, **63**, 789–808.
- 15 Q. Zhao, L. Wang, R. Cheng, L. Mao, R. D. Arnold, E. W. Howerth, Z. G. Chen and S. Platt, *Theranostics*, 2012, 2, 113–121.
- 16 X. Li, Y. Hu, J. Xiao, D. Cheng, Y. Xiu and H. Shi, *Nanoscale Res. Lett.*, 2015, **10**, 367.
- 17 D. Kim, S. Park, J. H. Lee, Y. Y. Jeong and S. Jon, *J. Am. Chem. Soc.*, 2007, **129**, 7661–7766.
- 18 M. Kodiha, Y. M. Wang, E. Hutter, D. Maysinger and U. Stochaj, *Theranostics*, 2015, 5, 357–370.
- 19 H. Hinterwirth, G. Stubiger, W. Lindner and M. Lammerhofer, *Anal. Chem.*, 2013, **85**, 8376–8384.
- 20 M. Zhu, X. Cai, M. Fujitsuka, J. Zhang and T. Majima, *Angew. Chem., Int. Ed.*, 2017, **56**, 2064–2068.
- 21 Z. Zhang, J. Wang and C. Chen, *Adv. Mater.*, 2013, 25, 3869–3880.
- 22 M. S. Yavuz, Y. Y. Cheng, J. Y. Chen, C. M. Cobley, Q. Zhang, M. Rycenga, J. W. Xie, C. Kim, K. H. Song, A. G. Schwartz, L. H. V. Wang and Y. N. Xia, *Nat. Mater.*, 2009, **8**, 935–939.
- 23 S. E. Skrabalak, J. Y. Chen, Y. G. Sun, X. M. Lu, L. Au, C. M. Cobley and Y. N. Xia, *Acc. Chem. Res.*, 2008, 41, 1587–1595.
- 24 A. M. Alkilany, L. B. Thompson, S. P. Boulos, P. N. Sisco and C. J. Murphy, *Adv. Drug Delivery Rev.*, 2012, **64**, 190–199.
- 25 M. A. Mackey, M. R. Ali, L. A. Austin, R. D. Near and M. A. El-Sayed, J. Phys. Chem. B, 2014, 118, 1319–1326.
- 26 Y. Tian, S. Luo, H. J. Yan, Z. G. Teng, Y. W. Pan, L. Y. Zeng, J. Wu, Y. J. Li, Y. Liu, S. J. Wang and G. M. Lu, *J. Mater. Chem. B*, 2015, 3, 4330–4337.
- 27 Y. Liu, J. R. Ashton, E. J. Moding, H. Yuan, J. K. Register, A. M. Fales, J. Choi, M. J. Whitley, X. Zhao, Y. Qi, Y. Ma, G. Vaidyanathan, M. R. Zalutsky, D. G. Kirsch, C. T. Badea and T. Vo-Dinh, *Theranostics*, 2015, 5, 946–960.

- 28 H. Liu, D. Chen, L. Li, T. Liu, L. Tan, X. Wu and F. Tang, *Angew. Chem., Int. Ed.*, 2011, **50**, 891–895.
- 29 S. Lal, S. E. Clare and N. J. Halas, *Acc. Chem. Res.*, 2008, **41**, 1842–1851.
- 30 S. J. Oldenburg, R. D. Averitt, S. L. Westcott and N. J. Halas, *Chem. Phys. Lett.*, 1998, 288, 243–247.
- 31 C. Fu, C. He, L. Tan, S. Wang, L. Shang, L. Li, X. Meng and H. Liu, *Sci. Bull.*, 2016, **61**, 282–291.
- 32 Z. C. Xu, Y. L. Hou and S. H. Sun, *J. Am. Chem. Soc.*, 2007, **129**, 8698–8699.
- 33 T. Zhou, B. Wu and D. Xing, J. Mater. Chem., 2012, 22, 470-477.
- 34 X. J. Ji, R. P. Shao, A. M. Elliott, R. J. Stafford, E. Esparza-Coss, J. A. Bankson, G. Liang, Z. P. Luo, K. Park, J. T. Markert and C. Li, *J. Phys. Chem. C*, 2007, **111**, 6245– 6251.
- 35 X. Wang, H. Liu, D. Chen, X. Meng, T. Liu, C. Fu, N. Hao, Y. Zhang, X. Wu, J. Ren and F. Tang, ACS Appl. Mater. Interfaces, 2013, 5, 4966–4971.
- 36 Y. Jin, C. Jia, S. W. Huang, M. O'Donnell and X. Gao, *Nat. Commun.*, 2010, 1, 41.
- 37 N. Kostevšek, K. Žužek Rožman, M. S. Arshad, M. Spreitzer, S. Kobe and S. Šturm, *J. Phys. Chem. C*, 2015, **119**, 16374– 16382.
- 38 L. Wang, J. Bai, Y. Li and Y. Huang, Angew. Chem., Int. Ed., 2008, 47, 2439–2442.
- 39 J. Park, K. An, Y. Hwang, J. G. Park, H. J. Noh, J. Y. Kim, J. H. Park, N. M. Hwang and T. Hyeon, *Nat. Mater.*, 2004, 3, 891–895.
- 40 H. L. Ding, Y. X. Zhang, S. Wang, J. M. Xu, S. C. Xu and G. H. Li, *Chem. Mater.*, 2012, 24, 4572–4580.
- 41 C. S. Levin, C. Hofmann, T. A. Ali, A. T. Kelly, E. Morosan, P. Nordlander, K. H. Whitmire and N. J. Halas, *ACS Nano*, 2009, 3, 1379–1388.
- 42 L. Li, S. Fu, C. Chen, X. Wang, C. Fu, S. Wang, W. Guo, X. Yu, X. Zhang, Z. Liu, J. Qiu and H. Liu, *ACS Nano*, 2016, **10**, 7094– 7105.